LIVNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
LivaNova PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$78.14+0.56 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $4.40B
- P/E (TTM)
- 23.1
- Dividend yield
- –
LivaNova PLC revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiopulmonary | $840.02M | $817.72M | $785.39M | $760.48M | $729.50M | $703.94M | $683.51M | $667.14M | $643.86M | $624.26M | $604.11M | $589.16M | 57.1% | +15.2% |
| Neuromodulation | $620.98M | $605.71M | $592.81M | $577.70M | $568.04M | $559.24M | $554.22M | $553.54M | $542.55M | $532.86M | $519.71M | $509.92M | 42.2% | +9.3% |
| Advanced Circulatory Support | – | – | – | – | – | – | – | – | – | – | $40.32M | $39.84M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuromodulation | $212.19M | $207.28M | $215.47M | $208.84M | $202.19M | – | $195.31M | – | – | – | – | – | +4.9% |
| Cardiopulmonary | $110.42M | $113.68M | $108.30M | $101.64M | $98.61M | – | $76.85M | – | – | – | – | – | +12.0% |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $765.96M | $755.09M | $739.57M | $723.18M | $712.56M | $703.63M | $695.08M | $693.21M | $674.96M | $655.40M | $635.04M | $615.62M | 52.1% | +7.5% |
| Rest of World | $405.39M | $393.24M | $379.30M | $370.00M | $355.86M | $346.36M | $338.32M | $327.56M | $318.48M | $310.15M | $303.71M | $304.13M | 27.5% | +13.9% |
| Europe | $300.17M | $285.13M | $269.18M | $255.78M | $240.91M | $225.39M | $220.03M | $220.98M | $216.29M | $219.49M | $214.79M | $198.54M | 20.4% | +24.6% |
From the segment and revenue-disaggregation notes of LivaNova's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.